Legal Representation
Attorney
DONNA J. BUNTON
Application History
45 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 30, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| Jul 30, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Jun 21, 2024 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Jun 21, 2024 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Jun 18, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jun 18, 2024 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jun 18, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Feb 9, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Feb 9, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 9, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| Nov 9, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Aug 9, 2023 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Aug 9, 2023 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Aug 9, 2023 | CNRT | W | SU - NON-FINAL ACTION - WRITTEN | Loading... |
| Jul 19, 2023 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Jul 19, 2023 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Jun 23, 2023 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Jun 23, 2023 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| May 4, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 2, 2023 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| May 2, 2023 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| May 2, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 4, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Nov 2, 2022 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Nov 2, 2022 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Nov 2, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| May 4, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| May 2, 2022 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| May 2, 2022 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| May 2, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Nov 2, 2021 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Sep 22, 2021 | OP.T | T | OPPOSITION TERMINATED NO. 999999 | Loading... |
| Sep 22, 2021 | OP.D | T | OPPOSITION DISMISSED NO. 999999 | Loading... |
| Sep 22, 2021 | TMBN | T | TTAB RELEASE CASE TO TRADEMARKS | Loading... |
| Jul 23, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 6, 2020 | OP.I | T | OPPOSITION INSTITUTED NO. 999999 | Loading... |
| Jan 9, 2020 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Jan 7, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 7, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 18, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Dec 3, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 22, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 17, 2019 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED | Loading... |
| Sep 16, 2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Sep 7, 2019 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of viral infections, immune disorders, cancer and ME/CFS; intravenous solution for use in the treatment of injuries resulting from surgery, thermal accidents or burns; Interferons; Parenterally administered interferon for use in treating viral diseases, immunological disorders and cancer; Pharmaceutical products, namely, pharmaceutical preparations for treatment of viral and infectious diseases, cancer, immune disorders and ME/CFS; intranasal solutions for use as a vaccine adjuvant, all of the foregoing primarily available by prescription
First Use Anywhere:
Jun 7, 2023
First Use in Commerce:
Jun 7, 2023
Class 042
Pharmaceutical research and development; Pharmaceutical research and development of drugs for the treatment of cancers, viral diseases, immunological disorders and ME/CFS
First Use Anywhere:
20190900
First Use in Commerce:
20190900
Additional Information
Design Mark
The mark consists of a design of two curves with four horizontal lines between them, with the words "AIM ImmunoTech" to the right of the design and the word "AIM" above the word "ImmunoTech".
Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
AIM IMMUNO TECH
Classification
International Classes
005
042